Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Immuno-Oncology Europe 2019

Saso Cemerski's Biography

Saso Cemerski, Senior Director, CUE Biopharma

Saso Cemerski is a Senior Director at Cue Biopharma and leads the company’s Immuno-Oncology Discovery and Translational Immunology team. His focus is on early pipeline development, building preclinical packages for assets in the immuno-oncology pipeline and developing adequate translational biomarker strategies to test key hypotheses in the clinic. Prior to joining Cue Biopharma, Dr. Cemerski held positions at Xencor, BMS and most recently, MSD where he led the STING agonist programs and participated as a core-team member of the anti-LAG-3 program, both of which are currently in the clinic. Dr. Cemerski did his postdoctoral training at Washington University in St Louis, Missouri where he worked to elucidate how immune synapses control T cell activation.

Saso Cemerski Image

Immuno-STATs™: A Novel Biologics Platform for Antigen-Specific Immunotherapy

Tuesday, 29 October 2019 at 11:30

Add to Calendar ▼2019-10-29 11:30:002019-10-29 12:30:00Europe/LondonImmuno-STATs™: A Novel Biologics Platform for Antigen-Specific ImmunotherapyImmuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The

Immuno-STATs are proprietary biologics that incorporate, in a single molecular framework, key signals needed to selectively modulate antigen-specific T cells: namely, the pMHC-complex and relevant co-stimulatory/co-inhibitory signals, dependent upon the disease indication. The modularity and versatility of the platform allows for incorporation of diverse HLA alleles, different T cell epitopes along with various biologically relevant activating or regulatory signals. This ability to generate polyspecific therapeutic molecules enables targeting diverse geographical patient populations encompassing numerous disease indications. Harnessing selective immune-targeting while avoiding broad non-specific modulation of the immune system should provide a superior safety and therapeutic profile. Mechanistic data to this end will be discussed. The lead clinical candidate CUE-101 is comprised of HLA-A*0201, genetically bound to a HPV16 epitope (E7 protein, peptide 11-20), along with affinity-attenuated human interleukin-2 to selectively activate and expand HPV16 E711-20-specific CD8+ T cells for HPV-driven malignancies.

Add to Calendar ▼2019-10-28 00:00:002019-10-29 00:00:00Europe/LondonImmuno-Oncology Europe 2019Immuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The